Using Combination csDMARDs in PsA

Dr. Eric Ruderman offers his perspective on abstract OP0093 (Effectiveness of Combination csDMARD Therapy in Psoriatic Arthritis Using Data from the MONITOR-PsA Cohort), abstract OP0106 (Long term outcomes of methotrexate and leflunomide combination therapy compared to methotrexate monotherapy in psoriatic arthritis: A follow-up study of the COMPLETE PsA trial), abstract POS0106 (REAL-WORLD TREAT-TO-TARGET STRATEGY IN PSORIATIC ARTHRITIS: 48-WEEK RESULTS FROM THE MONITOR-PsA COHORT), presented at EULAR 2025 in Barcelona, Spain.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×